Safety and efficacy of TRC150094 in treatment of cardio-metabolic risk in overweight/obese diabetic subjects with dyslipidemia

Trial Profile

Safety and efficacy of TRC150094 in treatment of cardio-metabolic risk in overweight/obese diabetic subjects with dyslipidemia

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs TRC 150094 (Primary)
  • Indications Diabetes mellitus; Dyslipidaemias; Insulin resistance; Metabolic syndrome; Obesity
  • Focus Therapeutic Use
  • Sponsors Torrent Pharmaceuticals
  • Most Recent Events

    • 16 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top